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Abstract
Aims/hypothesis—We compared the associations of circulating biomarkers of inflammation, 
endothelial and adipocyte dysfunction and coagulation with incident diabetes in the placebo, 
lifestyle and metformin intervention arms of the Diabetes Prevention Program, a randomised 
clinical trial, to determine whether reported associations in general populations are reproduced in 
individuals with impaired glucose tolerance, and whether these associations are independent of 
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traditional diabetes risk factors. We further investigated whether biomarker–incident diabetes 
associations are influenced by interventions that alter pathophysiology, biomarker concentrations 
and rates of incident diabetes.
Methods—The Diabetes Prevention Program randomised 3234 individuals with impaired 
glucose tolerance into placebo, metformin (850 mg twice daily) and intensive lifestyle groups and 
showed that metformin and lifestyle reduced incident diabetes by 31% and 58%, respectively 
compared with placebo over an average follow-up period of 3.2 years. For this study, we measured 
adiponectin, leptin, tissue plasminogen activator (as a surrogate for plasminogen activator inhibitor 
1), high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, fibrinogen, E-
selectin and intercellular adhesion molecule 1 at baseline and at 1 year by specific immunoassays. 
Traditional diabetes risk factors were defined as family history, HDL-cholesterol, triacylglycerol, 
BMI, fasting and 2 h glucose, HbA1c, systolic blood pressure, inverse of fasting insulin and 
insulinogenic index. Cox proportional hazard models were used to assess the effects of each 
biomarker on the development of diabetes assessed semi-annually and the effects of covariates on 
these.
Results—E-selectin, (HR 1.19 [95% CI 1.06, 1.34]), adiponectin (0.84 [0.71, 0.99]) and tissue 
plasminogen activator (1.13 [1.03, 1.24]) were associated with incident diabetes in the placebo 
group, independent of diabetes risk factors. Only the association between adiponectin and diabetes 
was maintained in the lifestyle (0.69 [0.52, 0.92]) and metformin groups (0.79 [0.66, 0.94]). E-
selectin was not related to diabetes development in either lifestyle or metformin groups. A novel 
association appeared for change in IL-6 in the metformin group (1.09 [1.021, 1.173]) and for 
baseline leptin in the lifestyle groups (1.31 [1.06, 1.63]).
Conclusions/interpretation—These findings clarify associations between an extensive group 
of biomarkers and incident diabetes in a multi-ethnic cohort with impaired glucose tolerance, the 
effects of diabetes risk factors on these, and demonstrate differential modification of associations 
by interventions. They strengthen evidence linking adiponectin to diabetes development, and argue 
against a central role for endothelial dysfunction. The findings have implications for the 
pathophysiology of diabetes development and its prevention.
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Introduction
Although type 2 diabetes is known to result from deficits of insulin secretion and action, the 
metabolic disturbances underlying these abnormalities remain incompletely understood. 
Evidence implicates activation of inflammatory pathways in adipose and other tissues, with 
accompanying vascular endothelial, adipocyte and coagulant dysfunction, in the 
pathophysiology of diabetes (1). Population studies show that circulating biomarkers of 
these processes associate with incident diabetes, (2) but few studies have been carried out in 
cohorts with impaired glucose tolerance. It remains unclear whether such associations are 
distinct from the traditional diabetes risk factors (DRFs), as weight gain, insulin resistance, 
dyslipidaemia and hyperglycaemia have each been shown to activate pathways leading to 
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inflammation, endothelial dysfunction and imbalanced coagulation (1). Furthermore, there is 
limited information on the effects of interventions that slow progression to diabetes on 
biomarker–incident diabetes associations. An intervention-induced alteration of an 
association between a given biomarker and incident diabetes may provide a deeper 
perspective on the relationship of the biomarker to the development of diabetes and on the 
mechanism(s) underlying the prevention effect.
The Diabetes Prevention Program (DPP; ClinicalTrials.gov registration no. NCT00004992) 
was a randomised multicentre clinical trial that demonstrated that both intensive lifestyle 
modification (ILS) and metformin therapy can reduce incident diabetes in high-risk 
individuals compared with standard care (3). Well-recognised risk factors for diabetes 
development, namely increased BMI, dysglycaemia and impairments of insulin secretion 
and action were shown to be determinants of incident diabetes in all groups (4). We report 
here on the associations between incident diabetes and a composite group of biomarkers of 
inflammation, coagulant imbalance and endothelial and adipocyte dysfunction in the DPP 
cohort with prediabetes, exploring treatment-specific effects and relationships with 
established DRFs.
Methods
Study participants and procedures
Eligibility criteria, design, methods and primary results of the DPP have been reported in 
detail elsewhere (3). The selection criteria included: age ≥ 25 years, BMI ≥ 24 kg/m² (≥22 
kg/m² in Asian Americans), fasting plasma glucose levels between 5.3 and 6.9 mmol/l (<6.9 
mmol/l in American Indians) and impaired glucose tolerance (2 h post-load glucose of 7.8–
11.0 mmol/l). Written informed consent was obtained from all participants before screening, 
consistent with the Declaration of Helsinki and the guidelines of each centre’s institutional 
review board. In total, 3234 participants were randomly assigned to one of three intervention 
groups: metformin 850 mg twice daily; placebo twice daily; or an intensive programme of 
lifestyle modification (ILS). Allocation to metformin and placebo groups was double 
blinded. The goals of ILS were to achieve and maintain weight reduction of ≥ 7% through 
consumption of a low-calorie, low-fat diet and to engage in moderate physical activity for ≥ 
150 min/week. The placebo group was managed according to standard healthcare 
recommendations only. Diabetes was diagnosed by an annual OGTT or a semi-annual 
fasting glucose test according to American Diabetes Association criteria (5) throughout the 
follow-up period of 3.2 years. The diagnosis required confirmation by a second test, usually 
within 6 weeks. Semi-annual measurements of weight, BP and fasting glucose and annual 
measurements of HDL-cholesterol, triacylglycerol and HbA1c, and glucose tolerance by 
OGTT, were performed.
Clinical and metabolic variables
Standardised interviewer-administered questionnaires were used to obtain demographic 
information, and BP and anthropometrics (BMI and waist circumference) were measured by 
standard techniques. Glucose, insulin, HbA1c and biomarker measurements were performed 
at the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University 
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of Washington, Seattle, WA, USA) as previously reported (3, 4). The biomarker 
measurements other than fibrinogen, tissue plasminogen activator (tPA) and C-reactive 
protein (CRP) were specifically performed for the current study, whereas all other 
assessments were part of the original DPP study (3). Indirect measures of insulin resistance 
defined as inverse of fasting insulin (IFI) and insulin secretory capacity defined as 
insulinogenic index (IGI; 30–0 min change in plasma insulin over 30–0 min change in 
plasma glucose) were obtained from the annual OGTT (4). A total of 3195 samples were 
available for biomarker assay at baseline and 3009 samples had paired measurements at both 
baseline and 1 year.
We evaluated at least two biomarkers representing each of the distinct biological processes 
of inflammation, procoagulant state and endothelial and adipocyte dysfunction for this study. 
Markers of inflammation included high-sensitivity CRP measured immunochemically using 
Dade-Behring reagent on the Behring Nephelometer autoanalyser (Deerfield, IL, USA), and 
IL-6 and Monocyte chemoattractive protein 1 (MCP-1) measured by ELISAs from R&D 
Systems (Minneapolis, MN, USA). Procoagulant state was assessed by fibrinogen levels in 
plasma (using the same method as CRP). Total tPA level measured in citrated plasma using 
an ELISA (Asserachrom tPA; Diagnostica Stago, Parsippany, NJ, USA) was used as a 
surrogate for plasminogen activator inhibitor 1 (PAI-1), as previously documented (6). 
Endothelial dysfunction was assessed using soluble E-selectin (sE-selectin) and soluble 
intercellular adhesion molecule 1 (sICAM-1), measured by an R&D Systems ELISA. 
Adipocyte dysfunction was assessed by total adiponectin levels, measured using a latex 
particle-enhanced turbidimetric assay (Otsuka Pharmaceutical, Tokyo, Japan), and leptin 
levels, measured by radioimmunoassay (Millipore, Darmstadt, Germany). The within-run 
and between-run CVs for all biomarker assays ranged between 2.10% and 7.40%, and 
2.60% and 9.25%, respectively.
Statistical analysis
We applied the intent-to-treat approach to analysis. Differences in baseline and 1 year 
change in biomarkers among treatment groups were assessed by the median test using 
quantile regression (7) and ANOVA, respectively, with the significance level set at 0.01 and 
using unadjusted p values for the three pairwise treatment group comparison. This is slightly 
more conservative than the Bonferroni significance level of 0.0167 for three tests (i.e. 
0.05/3). Spearman correlations were used to describe the bivariate relationships among the 
anthropometric and metabolic variables, with adjustment for demographic factors. 
Traditional DRFs were defined as family history of diabetes, BMI, waist circumference, IFI 
and IGI, fasting and 2 h glucose, HbA1c, HDL-cholesterol, triacylglycerol and systolic BP 
(SBP). BMI was chosen over waist circumference for Cox models as, in our population, the 
two measurements predict incident diabetes equally well (8).
We assessed the distributional characteristics of each biomarker (electronic supplementary 
material [ESM] Fig 1) and used natural log transformations for CRP, IL-6 and IFI. 
Correlations and multicollinearity among biomarkers within the same pathway 
(inflammation, coagulation, endothelial dysfunction and adipose dysregulation) were 
assessed to ensure it was appropriate to include them in the same model. None of the 
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biomarkers was found to be collinear. Missing data were assumed missing at random. Cox 
proportional hazards models were used to assess the effects of each biomarker on the 
development of diabetes. The added effects of biomarker change at 1 year were also 
assessed in separate models, though HbA1c and fasting glucose were excluded in this 
analysis as the outcome was diabetes. Graphical procedures were used to examine the 
proportionality assumption. HRs are expressed per 1 standard deviation. For the association 
of biomarkers and incident diabetes, we set a nominal significance level of 0.05 and for tests 
of heterogeneity between groups, p<0.1. We deem these analyses as both validation of 
previously reported associations in general populations and exploratory to assess possible 
moderating effects of treatment, although the study is underpowered.
Results
Baseline and 1 year change in traditional diabetes risk factors and biomarker values
The results are presented in Table 1. The DPP cohort included 3234 participants with mean 
age of 51 years, 67% were women and 45% were ethnic minorities and a positive family 
history was present in 70% of the cohort. Table 1 depicts BMI, waist circumference, SBP, 
HDL-cholesterol, triacylglycerol, fasting and 2 h glucose, HbA1c, IFI, IGI and biomarker 
values at baseline for the entire cohort that had baseline samples available for biomarker 
measurements (n=3195), and 1 year changes in these variables by intervention group and 
grouped according to the biological pathways represented. The baseline biomarker values 
are displayed by intervention group in ESM Table 1. As there were no differences among 
randomised treatment groups at baseline, median baseline values with interquartile ranges 
(IQRs) for the entire cohort are shown. As previously reported (3), ILS and metformin 
improved BMI, HDL-cholesterol, fasting glucose, HbA1c and fasting insulin compared with 
placebo at 1 year, with ILS having a more robust effect, while ILS only reduced 2 h glucose, 
SBP and triacylglycerol. The 1 year change in all of the evaluated biomarkers differed 
among treatment groups when the biomarkers were considered individually. For markers of 
adipocyte dysfunction, adiponectin and leptin were improved by ILS vs placebo and 
metformin, whereas metformin only reduced leptin (and not adiponectin) compared with 
placebo. Among inflammatory markers, CRP was reduced only by ILS compared with 
placebo and metformin, while IL-6 was decreased by both active intervention groups. For 
the procoagulant markers, tPA was reduced by both ILS and metformin vs placebo and more 
in the ILS group than in the metformin group, while fibrinogen was lowered only by ILS 
compared with placebo and metformin. The markers of endothelial dysfunction sE-selectin 
and sICAM-1 were reduced by ILS compared with the other two interventions, whereas 
metformin only reduced sICAM-1 (and not sE-selectin) vs placebo.
Correlations between traditional diabetes risk factors and biomarkers
Figure 1 depicts Spearman correlation coefficients between biomarkers and DRFs (BMI, 
waist circumference, fasting glucose, HbA1c, 2 h plasma glucose, IGI, IFI, HDL-cholesterol, 
tracylglycerol and SBP) at baseline, ordered by r values for BMI. All of the evaluated 
biomarkers correlated significantly with BMI, waist circumference and IFI. Leptin, CRP, 
and IL-6 and fibrinogen had the strongest correlations with BMI and waist circumference, 
while adiponectin (directly), and tPA and leptin (inversely) were most strongly correlated 
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with IFI. Associations between biomarkers and IGI were weaker, with leptin (directly) and 
adiponectin (inversely) more strongly associated than others. Associations with fasting and 2 
h glucose were weak or non-existent except for moderate associations for adiponectin and 
tPA with fasting glucose. HbA1c was more strongly correlated with the inflammatory 
markers CRP, IL-6, MCP-1 and fibrinogen than were the glucose measurements. sICAM-1 
and sE-selectin showed similar moderate associations with BMI and waist circumference 
and inversely with IFI. Overall, these observations indicate that the biomarkers evaluated 
were more strongly but differentially related to adiposity and insulin resistance than to 
measures of glycaemia or insulin secretion.
Correlations among biomarkers at baseline
Figure 2 illustrates correlations between baseline biomarkers. Strong associations were 
noted between CRP, IL-6, leptin and fibrinogen. The endothelial dysfunction markers 
sICAM-1 and sE-selectin correlated with each other and had similar associations with IL-6 
and tPA; sICAM-1 was moderately correlated with CRP and sE-selectin more weakly so. 
Adiponectin correlated inversely with tPA and sE-selectin but had weak or no associations 
with inflammatory markers (CRP, IL-6 and MCP-1). These observations suggest that the 
inflammatory markers and fibrinogen tended to form one group of interrelated factors, 
whereas adiponectin, tPA and endothelial function markers tended to form a separate group, 
with sICAM-1 overlapping the two groups.
Biomarkers as predictors of incident diabetes and effects of interventions
Table 2 presents Cox proportional hazards models testing the effects of baseline biomarker 
HRs for incident diabetes by intervention group. There were 1344 participants who 
developed diabetes (506 in the placebo group, 446 in the metformin grop and 392 in the ILS 
group). Each baseline biomarker was tested in three successive stepwise models. Model 1 
describes the HR for each baseline biomarker adjusted for demographic factors only (age at 
randomisation, sex, race/ethnicity). Model 2 adds the effect of baseline DRFs, which include 
family history of diabetes, HbA1c, fasting glucose, BMI, IGI, IFI, SBP, triacylglycerol and 
HDL-cholesterol. When waist circumference was substituted for BMI in these models, there 
were no significant differences in the HRs and so the data are shown with only BMI in the 
model. Fasting glucose was chosen over 2 h glucose as it associated better with the 
biomarkers, and is more relevant clinically. Model 3 adds the 1 year changes in non-
glycaemic DRFs (BMI, IGI, IFI, SBP, triacylglycerol, HDL-cholesterol). A final model, 
which included baseline and year 1 changes in all biomarkers and DRFs to evaluate 
biomarker interactions, is shown in ESM Table 2. A separate analysis tested whether 1 year 
biomarker changes adjusted for demographics and DRFs associated with incident diabetes 
(Fig. 3). We observed no significant associations for fibrinogen or MCP-1 with incident 
diabetes in any group; therefore, these data are not shown. Models were evaluated separately 
for each treatment group to explore treatment-specific mediators of treatment effects.
Placebo group—Adiponectin was inversely and CRP, sE-selectin, sICAM-1 and tPA 
values were directly associated with incident diabetes after adjustment for demographic 
factors (model 1); although attenuated, this association remained significant for adiponectin 
(HR 0.84 [95% CI 0.71, 0.99]), tPA (1.10 [1.01, 1.21]) and sE-selectin (1.16 [1.04, 1.28]) 
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after adjustment for baseline DRFs (model 2), and both sE-selectin (1.19 [1.06, 1.34]) and 
tPA (1.13 [1.03, 1.24]) remained significantly associated after adjustment for the modest 
DRF changes in this group (model 3) and also after all other biomarkers were included in 
the model (ESM Table 2). Neither leptin nor IL-6 demonstrated any relationship with 
incident diabetes. In the change analysis (Fig. 3a, b), adiponectin change was associated 
with diabetes even after adjustment for risk factor changes at 1 year.
ILS group—Baseline adiponectin (inversely) and leptin (directly) were robustly associated 
with incident diabetes independent of DRFs and in the case of adiponectin even after 
changes in DRFs at 1 year (model 3) as well as after adjustment for all other biomarkers 
(ESM Table 2). As in the placebo group, baseline CRP was associated with diabetes 
development as was tPA (model 1), but both lost significance when DRFs were included in 
the model (model 2). A major difference between the ILS and placebo groups was the 
absence of an association between sE-selectin and incident diabetes. Although sICAM-1 
was not associated with incident diabetes in models 1 and 2, this became significant after 
adjustment for changes in DRFs (model 3). The changes in biomarkers at 1 year, with the 
exception of IL-6, all associated with incident diabetes (Fig. 3a) but all lost significance, 
including adiponectin, after risk factors changes were included in the analysis (Fig. 3b).
Metformin group—In parallel with findings in the placebo and ILS, baseline adiponectin 
was inversely associated with incident diabetes in models 1 and 2 and, like ILS, this 
association persisted in model 3 and after adjustment for other biomarkers (ESM Table 2). 
CRP was directly associated only in model 1. Like ILS, metformin differed from the placebo 
in that sE-selectin did not associate with incident diabetes but, unlike ILS, neither baseline 
leptin, tPA nor sICAM-1 was associated. In the change analysis, as for the ILS group, CRP, 
sE-selectin and tPA associated with incident diabetes (Fig. 3a) but this association was lost 
after adjustment for changes in DRFs (Fig 3b). Only in the metformin goup was change in 
IL-6 associated with incident diabetes even after adjustment for change in DRFs (1.09 
[1.021, 1.173]) (HR [95% CI]).
In all instances in which biomarker associations with incident diabetes differed between 
groups, heterogeneity by group was present.
Discussion
In this study of biomarker associations with incident diabetes, we first sought to determine 
whether previously well-documented findings in population studies applied to a high-risk 
population with impaired glucose tolerance, such as that recruited in the DPP. Using the 
placebo group that received standard care only, we confirmed that baseline sE-selectin, 
adiponectin, tPA, sICAM-1 and CRP were all significantly associated with incident diabetes, 
as has been reported in previous population surveys (2, 8–16) but, unlike another study (17), 
leptin and IL-6 were not. The similarities of our findings to previously published reports 
may not be surprising as incident diabetes presumably develops from undiagnosed 
prediabetes in population studies. Although we used tPA as a surrogate for PAI-1, it 
performs well as a marker of incident diabetes (16). These observations confirm the 
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generalisability of the biomarker associations we found and, by inference, support the 
generalisability of the treatment-specific associations that we observed.
Adiponectin, tPA and sE-selectin had the strongest associations with incident diabetes in the 
placebo group. Importantly, we were able to show that these associations, unlike those for 
CRP and sICAM-1, were at least partly independent of traditional DRFs. This suggests that 
the pathways through which adiponectin, tPA and sE-selectin are linked to incident diabetes 
operate, in part, independently of factors such as obesity, insulin resistance, dyslipidaemia 
and dysglycaemia at baseline, whereas those marked by CRP and sICAM-1 do not. 
Although adiponectin is strongly related to insulin resistance (18), the fact that its 
association with diabetes development was largely independent of IFI, an admittedly 
imperfect measure of insulin resistance, raises the possibility that its association with 
incident diabetes extends to other pathophysiological pathways (19). PAI-1 is thought to 
play a major role in fibrinolysis (20), but has also been implicated in vascular remodelling, 
adipocyte differentiation and macrophage function (21), all of which could underlie the 
relationship between tPA and diabetes independent of traditional DRFs and their changes. 
The association of sE-selectin with incident diabetes may reflect a linkage between 
endothelial dysfunction and development of diabetes (22) that is not accounted for by DRFs 
and their changes, and appeared also to be independent of the other biomarkers. However, 
this association need not imply a direct role for endothelial dysfunction in diabetes 
development. Instead, it could reflect the specificity of sE-selectin for vascular damage (22) 
that has been proposed to be part of the common soil in which vascular disease and type 2 
diabetes emerge (23).
Given these findings, it was of interest to determine whether these well-established 
biomarker associations with incident diabetes were modified or remained intact after ILS 
and metformin interventions. At issue is whether the favourable changes in biomarker levels, 
DRFs and incident diabetes induced by these two different interventions affect the pathways 
reflected by these biomarkers in a manner that alters the biomarker–incident diabetes 
associations seen in the non-intervened state and whether this was similar or different in ILS 
vs metformin groups. Persistence or strengthening of these associations with ILS or 
metformin intervention would bolster evidence in support of a central robust 
pathophysiological role for the underlying pathway or pathways marked by the biomarker in 
diabetes development. On the other hand, loss of one or more of these associations in the 
ILS or metformin groups could constitute evidence lessening the relevance of that biomarker 
and the biochemical pathway it reflects, or alternatively that the biomarker reflects only one 
of multiple processes related to diabetes development that are differentially affected by these 
interventions.
With these considerations in mind, we found first that baseline adiponectin was even more 
strongly associated with incident diabetes in both ILS and metformin groups than in the 
placebo group, even after full adjustment for DRFs as well as their changes at 1 year and 
without evidence of heterogeneity by intervention group. These results, which we have 
partly reported previously (24) and which were independent of the other biomarkers, argue 
for a direct strong relationship between adiponectin and incident diabetes (25) that remains 
intact with or without interventions that change pathophysiology. It was notable, however, 
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that although the ILS-induced adiponectin change was quite sizeable and was inversely 
related to diabetes development, this was no longer true after adjustment for risk factor 
changes. No associations with diabetes for the smaller adiponectin change in the metformin 
group were found. It is possible that baseline adiponectin levels reflect a metabolic setting 
that has a consistent and persisting ‘conditioning’ effect on diabetes development in all three 
different intervention scenarios, with the induced change in level resulting from ILS being 
more closely tied to changes in the metabolic state, such as an improvement in insulin 
sensitivity, than to the more distal effect on diabetes incidence per se.
Second, while baseline tPA had a similar association with incident diabetes in the ILS group 
to that in the placebo group, adjustment for DRFs attenuated this association and there was 
no association between tPA and diabetes development in the metformin group. Thus, in 
contrast to what was observed with adiponectin, it appears that ILS modifies diabetes 
development by weakening the link between tPA and incident diabetes noted in the placebo 
group, and metformin intervention disconnects it altogether. Furthermore, although the ILS-
induced change in tPA was strongly associated with incident diabetes in line with a previous 
report (26), as for the adiponectin change, this was accounted for by the effects of change in 
ILS-related risk factors on diabetes development. Interestingly, there was no relationship 
between the tPA change and incident diabetes in the metformin group, even though 
metformin led to a similar significant reduction in tPA as did ILS. Thus, it appears that the 
pathways marked by tPA (as a surrogate for PAI-1) are tied to diabetes development in the 
ILS group through its link to metabolic risk factors and are not independent of them, 
whereas in the metformin group, tPA was not even indirectly linked to incident diabetes 
through metabolic risk factors. This was initially unexpected as metformin, like ILS, did 
produce favourable changes in body weight, insulin resistance, dysglycaemia and 
dyslipidaemia, all of which are correlated with tPA. However, the principal mechanism by 
which metformin is thought to lower glucose levels involves direct inhibition of hepatic 
glucose production, an effect not known to be influenced by tPA/PAI-1. A final point is that 
although the effect of metformin to reduce tPA may not be related to its effect on diabetes 
incidence, the tPA effect may still mark a benefit of metformin in the prevention of vascular 
disease, with which tPA/PAI is thought to be associated (20).
A third observation is that while baseline sE-selectin was the most robust of the biomarker–
incident diabetes associations in the placebo, consistent with findings from the Framingham 
Study (12), and sICAM-1 was also associated although not after DRF adjustment, 
surprisingly there were no such associations in the ILS or metformin groups. This suggests 
that both active interventions reduce diabetes development in a manner that disconnects its 
association with the biomarkers of endothelial function that are present in the placebo group. 
Both interventions produced favourable changes in sICAM-1 and ILS lowered sE-selectin 
levels at 1 year, and the changes in these markers were associated with incident diabetes but 
not after adjustment for changes in DRFs. Thus, as for tPA, endothelial dysfunction was not 
directly related to development of diabetes in participants receiving ILS or metformin. While 
both ILS and metformin have been shown to favourably modify endothelial dysfunction 
using direct testing (27, 28), it is possible that this effect of these interventions may be more 
relevant for preventing progressive vascular damage than preventing incident diabetes.
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Last, we found that the active interventions exposed biomarker associations with incident 
diabetes not evident in the placebo group and in a differential manner. In the metformin 
group only, change in IL-6 independently associated with incident diabetes. Although 
baseline CRP, which is closely correlated with IL-6, and CRP changes in the active 
intervention groups were related to incident diabetes, this was not significant after 
adjustment for baseline DRFs and change in DRFs, respectively, and probably reflects the 
strong association of this biomarker with obesity (29). Also, in the ILS group only, baseline 
and change in leptin associated with incident diabetes in a manner independent of baseline 
DRFs, such as BMI, though these associations became non-significant after adjustment for 
changes in risk factors at 1 year. Although the meaning of these findings is unclear, they 
appear to reflect unique effects of ILS and metformin. In the case of metformin, one could 
speculate that the effect of metformin, but not ILS, on IL-6, an adipokine marker of 
inflammation, is uniquely linked to its effect on diabetes development independent of effects 
on body weight and insulin resistance; this would allow for the emergence of a selective 
association with incident diabetes in the metformin group only. Along the same lines, the 
novel leptin–incident diabetes association in the ILS group might reflect the possibility that 
participants with higher leptin levels were more likely to develop diabetes in the ILS group 
only, suggesting that lifestyle intervention exposed a hyperleptinaemic subgroup that was 
relatively resistant to the benefits of the intervention for development of diabetes, a 
hypothesis that deserves more direct testing.
Although the study design provided the opportunity to examine the associations between 
biomarkers and incident diabetes in a novel manner, there are several limitations to our 
findings. First, the study was not powered to test for differences in biomarker–incident 
diabetes associations between treatment groups. Second, we used surrogate measurements 
for insulin sensitivity and secretion because of the large number of participants in the study. 
Third, as our cohort was selected, the results are not generalisable to all people with 
prediabetes.
In summary, we show that among an extensive group of biomarkers, adiponectin, tPA and 
sE-selectin associate with incident diabetes independent of traditional DRFs in the placebo 
group, but that ILS and metformin interventions modify these associations significantly and 
differently, revealing new treatment-emergent biomarker associations. These observations 
attest to the complexity of the relationships between the processes reflected by these 
biomarkers and incident diabetes, offering clues to the further elucidation of the 
pathophysiology of diabetes development. These differences point to possible investigative 
opportunities for more precise approaches to targeting interventions for diabetes prevention.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Heat map showing Spearman correlations of biomarkers and DRFs at baseline. Correlations 
are characterised according to direction (positive in blue, negative in orange) and strength 
(intensity of colour). Spearman correlations with p>0.05 are indicated by a white 
background colour. FG, fasting glucose; HDL-C, HDL-cholesterol; PG, plasma glucose; TG, 
triacylglycerol; Waist, waist circumference
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Fig. 2. 
Heat map showing Spearman correlations between baseline biomarkers. Correlations are 
characterised according to direction (positive in blue, negative in orange) and strength 
(intensity of colour). Spearman correlations with p>0.05 are indciated by a white 
background colour
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Fig. 3. 
Adjusted HRs of change in biomarker for incident diabetes by treatment group. Treatment 
group-specific HR associations per 1 SD change in each biomarker for developing diabetes. 
(a) Adjustments include demographics (age at randomisation, sex, race/ethnicity), baseline 
DRFs (family history of diabetes, HbA1c, fasting glucose, BMI, IGI, IFI, SBP, 
triacylglycerol, HDL-cholesterol) and baseline biomarker. (b) Adjustments as in (a), with 
further adjustment for 1 year change in non-glycaemic DRFs (waist circumference, IGI, IFI, 
SBP, triacylglycerol, HDL-cholesterol). Circles, placebo; squares, metformin; and triangles, 
ILS
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